N.sup.6 -(epoxynorborn-2-yl) adenosines as A.sub.1 adenosine receptor agonists

• US 5,736,528 A
• Filed: 12/29/1995
• Issued: 04/07/1998
• Est. Priority Date: 10/28/1993
• Status: Expired due to Term

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Inventors: Olsson, Ray, Milner, Peter G., Belardinelli, Luiz, Baker, Stephen, Pfister, Jurg R., Scammells, Peter J.
• Primary Examiner(s): Kunz, Gary L.
• Application Number:
  US08/581,655
• Time in Patent Office: 830 Days
• Field of Search: 514/46, 514/821, 536/27.62
• US Class Current: 514/46
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/06 Antiarrhythmics
• CPC Class Codes: C07D 473/06 with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
• CPC Class Codes: C07H 19/16 Purine radicals

Abstract

N⁶ -(epoxynorborn-2-yl)adenosines are Al adenosine receptor agonists that are useful for controlling atrial fibrillation, ventricular rate in atrial flutter, supraventricular tachyarrhythmia, inhibiting A--V- nodal transmission in supraventricular tachycardia, and for normalizing ventricular rhythm and hemodynamics.

Claims

1. An adenosine epoxide compound which selectively and specifically binds an A₁ adenosine receptor to act as an agonist of said receptor, wherein said compound is an N⁶ -(epoxycycloalkyl) adenosine.

2. The compound, according to claim 1, wherein said compound has the formula ##STR9## wherein R₁ =alkyl of 1-4 carbons.

3. The compound, according to claim 1, wherein said compound is an N⁶ -(epoxynorbornyl) adenosine.

4. The compound, according to claim 1, wherein said compound has a formula selected from the group consisting of:

##STR10##

5. The compound, according to claim 1, wherein said compound has the structure:

##STR11##

6. A composition for use as an agonist of an A₁ adenosine receptor, said composition comprising an N⁶ -(epoxycycloalkyl) adenosine compound, or an analog, derivative, or isomer thereof;

and a pharmaceutically acceptable carrier.

7. The composition, according to claim 6, wherein said compound has the formula:

##STR12## wherein R₁ =alkyl of 1-4 carbons.

8. The composition, according to claim 6, wherein said compound is an N⁶ -(epoxynorbornyl) adenosine.

9. The composition, according to claim 6, wherein said compound has a formula selected from the group consisting of:

##STR13##

10. The composition, according to claim 6, wherein said compound has the formula:

##STR14##